---
document_datetime: 2025-11-23 08:05:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-teva-pharma.html
document_name: docetaxel-teva-pharma.html
version: success
processing_time: 0.0961472
conversion_datetime: 2025-12-23 20:57:59.305415
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Docetaxel Teva Pharma

[RSS](/en/individual-human-medicine.xml/65683)

##### Lapsed

This medicine's authorisation has lapsed

docetaxel

Medicine

Human

Lapsed

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 January 2014, the marketing authorisation for Docetaxel Teva Pharma (docetaxel) ceased to be valid in the European Union (EU). Docetaxel Teva Pharma is a generic medicinal product of Taxotere. Docetaxel Teva Pharma was never marketed in the EU after its initial marketing authorisation in January 2011.

In accordance with provisions of the sunset clause, the marketing authorisation of a medicinal product lapses if the product is not marketed in any of the EU Member States within three years of its initial authorisation. There are other generic medicinal products of Taxotere authorised and marketed in the EU. Docetaxel Teva Pharma was granted marketing authorisation in the EU on 21 January 2011 for the treatment of breast cancer, non-small cell lung cancer, and prostate cancer. The marketing authorisation holder was Teva Pharma B.V.

The European Assessment Report (EPAR) for Docetaxel Teva Pharma is updated to reflect the fact that the marketing authorisation is no longer valid.

Docetaxel Teva Pharma : EPAR - Summary for the public

Reference Number: EMA/698861/2010

English (EN) (219.53 KB - PDF)

**First published:** 03/02/2011

**Last updated:** 29/01/2014

[View](/en/documents/overview/docetaxel-teva-pharma-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-663)

български (BG) (318.47 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/bg/documents/overview/docetaxel-teva-pharma-epar-summary-public_bg.pdf)

español (ES) (275.38 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/es/documents/overview/docetaxel-teva-pharma-epar-summary-public_es.pdf)

čeština (CS) (294.23 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/cs/documents/overview/docetaxel-teva-pharma-epar-summary-public_cs.pdf)

dansk (DA) (274.22 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/da/documents/overview/docetaxel-teva-pharma-epar-summary-public_da.pdf)

Deutsch (DE) (275.97 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/de/documents/overview/docetaxel-teva-pharma-epar-summary-public_de.pdf)

eesti keel (ET) (268.9 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/et/documents/overview/docetaxel-teva-pharma-epar-summary-public_et.pdf)

ελληνικά (EL) (321.07 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/el/documents/overview/docetaxel-teva-pharma-epar-summary-public_el.pdf)

français (FR) (276.46 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/fr/documents/overview/docetaxel-teva-pharma-epar-summary-public_fr.pdf)

italiano (IT) (273.94 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/it/documents/overview/docetaxel-teva-pharma-epar-summary-public_it.pdf)

latviešu valoda (LV) (292.35 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/lv/documents/overview/docetaxel-teva-pharma-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (284.42 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/lt/documents/overview/docetaxel-teva-pharma-epar-summary-public_lt.pdf)

magyar (HU) (293.88 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/hu/documents/overview/docetaxel-teva-pharma-epar-summary-public_hu.pdf)

Malti (MT) (287.11 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/mt/documents/overview/docetaxel-teva-pharma-epar-summary-public_mt.pdf)

Nederlands (NL) (273.77 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/nl/documents/overview/docetaxel-teva-pharma-epar-summary-public_nl.pdf)

polski (PL) (287.03 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/pl/documents/overview/docetaxel-teva-pharma-epar-summary-public_pl.pdf)

português (PT) (275.95 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/pt/documents/overview/docetaxel-teva-pharma-epar-summary-public_pt.pdf)

română (RO) (274.87 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/ro/documents/overview/docetaxel-teva-pharma-epar-summary-public_ro.pdf)

slovenčina (SK) (300.68 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sk/documents/overview/docetaxel-teva-pharma-epar-summary-public_sk.pdf)

slovenščina (SL) (290.81 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sl/documents/overview/docetaxel-teva-pharma-epar-summary-public_sl.pdf)

Suomi (FI) (270.23 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/fi/documents/overview/docetaxel-teva-pharma-epar-summary-public_fi.pdf)

svenska (SV) (274.16 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sv/documents/overview/docetaxel-teva-pharma-epar-summary-public_sv.pdf)

## Product information

Docetaxel Teva Pharma : EPAR - Product Information

English (EN) (886.4 KB - PDF)

**First published:** 03/02/2011

**Last updated:** 29/01/2014

[View](/en/documents/product-information/docetaxel-teva-pharma-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-634)

български (BG) (3.94 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/bg/documents/product-information/docetaxel-teva-pharma-epar-product-information_bg.pdf)

español (ES) (960.66 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/es/documents/product-information/docetaxel-teva-pharma-epar-product-information_es.pdf)

čeština (CS) (2.44 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/cs/documents/product-information/docetaxel-teva-pharma-epar-product-information_cs.pdf)

dansk (DA) (1.74 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/da/documents/product-information/docetaxel-teva-pharma-epar-product-information_da.pdf)

Deutsch (DE) (1.89 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/de/documents/product-information/docetaxel-teva-pharma-epar-product-information_de.pdf)

eesti keel (ET) (1.71 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/et/documents/product-information/docetaxel-teva-pharma-epar-product-information_et.pdf)

ελληνικά (EL) (3.36 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/el/documents/product-information/docetaxel-teva-pharma-epar-product-information_el.pdf)

français (FR) (1.88 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/fr/documents/product-information/docetaxel-teva-pharma-epar-product-information_fr.pdf)

íslenska (IS) (1.88 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/is/documents/product-information/docetaxel-teva-pharma-epar-product-information_is.pdf)

italiano (IT) (1.91 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/it/documents/product-information/docetaxel-teva-pharma-epar-product-information_it.pdf)

latviešu valoda (LV) (2.77 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/lv/documents/product-information/docetaxel-teva-pharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.16 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/lt/documents/product-information/docetaxel-teva-pharma-epar-product-information_lt.pdf)

magyar (HU) (1.6 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/hu/documents/product-information/docetaxel-teva-pharma-epar-product-information_hu.pdf)

Malti (MT) (2.97 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/mt/documents/product-information/docetaxel-teva-pharma-epar-product-information_mt.pdf)

Nederlands (NL) (1.67 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/nl/documents/product-information/docetaxel-teva-pharma-epar-product-information_nl.pdf)

norsk (NO) (1.81 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/no/documents/product-information/docetaxel-teva-pharma-epar-product-information_no.pdf)

polski (PL) (2.45 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/pl/documents/product-information/docetaxel-teva-pharma-epar-product-information_pl.pdf)

português (PT) (2.08 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/pt/documents/product-information/docetaxel-teva-pharma-epar-product-information_pt.pdf)

română (RO) (1.96 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/ro/documents/product-information/docetaxel-teva-pharma-epar-product-information_ro.pdf)

slovenčina (SK) (2.43 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sk/documents/product-information/docetaxel-teva-pharma-epar-product-information_sk.pdf)

slovenščina (SL) (2.63 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sl/documents/product-information/docetaxel-teva-pharma-epar-product-information_sl.pdf)

Suomi (FI) (1.82 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/fi/documents/product-information/docetaxel-teva-pharma-epar-product-information_fi.pdf)

svenska (SV) (1.71 MB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sv/documents/product-information/docetaxel-teva-pharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/7/G 21/01/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Docetaxel Teva Pharma : EPAR - All Authorised presentations

English (EN) (162.12 KB - PDF)

**First published:** 03/02/2011

**Last updated:** 29/01/2014

[View](/en/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-942)

български (BG) (169.26 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/bg/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (162.51 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/es/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (168.77 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/cs/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (163.4 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/da/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (164.78 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/de/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (161.32 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/et/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (176.94 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/el/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_el.pdf)

français (FR) (162.49 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/fr/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (163.74 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/is/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (162.14 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/it/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (169.87 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/lv/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (163.26 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/lt/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (169.58 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/hu/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (169.93 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/mt/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (162.92 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/nl/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (164.22 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/no/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (169.44 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/pl/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (151.44 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/pt/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (163.29 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/ro/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (169.98 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sk/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (168.26 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sl/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (161.51 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/fi/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (163.89 KB - PDF)

**First published:**

03/02/2011

**Last updated:**

29/01/2014

[View](/sv/documents/all-authorised-presentations/docetaxel-teva-pharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Docetaxel Teva Pharma Active substance docetaxel International non-proprietary name (INN) or common name docetaxel Therapeutic area (MeSH)

- Carcinoma, Non-Small-Cell Lung
- Breast Neoplasms
- Prostatic Neoplasms

Anatomical therapeutic chemical (ATC) code L01CD02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Breast cancer**

Docetaxel Teva Pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

**Non-small-cell lung cancer**

Docetaxel Teva Pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.

Docetaxel Teva Pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.

**Prostate cancer**

Docetaxel Teva Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

## Authorisation details

EMA product number EMEA/H/C/002032

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10

Marketing authorisation issued 21/01/2011 Lapse of marketing authorisation 21/01/2014 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Docetaxel Teva Pharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (223.57 KB - PDF)

**First published:** 08/02/2012

**Last updated:** 29/01/2014

[View](/en/documents/procedural-steps-after/docetaxel-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Docetaxel Teva Pharma : EPAR - Public assessment report

Adopted

Reference Number: EMA/32518/2011

English (EN) (587.35 KB - PDF)

**First published:** 03/02/2011

**Last updated:** 29/01/2014

[View](/en/documents/assessment-report/docetaxel-teva-pharma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Docetaxel Teva Pharma

Adopted

Reference Number: EMA/CHMP/630633/2010

English (EN) (113.85 KB - PDF)

**First published:** 22/10/2010

**Last updated:** 22/10/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-docetaxel-teva-pharma_en.pdf)

**This page was last updated on** 21/01/2014

## Share this page

[Back to top](#main-content)